IBDEI15A ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20507,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,20507,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,20508,0)
 ;;=V13.4^^131^1289^27
 ;;^UTILITY(U,$J,358.3,20508,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20508,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,20508,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,20508,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,20509,0)
 ;;=V12.72^^131^1289^31
 ;;^UTILITY(U,$J,358.3,20509,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20509,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,20509,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,20509,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,20510,0)
 ;;=V12.59^^131^1289^30
 ;;^UTILITY(U,$J,358.3,20510,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20510,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,20510,1,5,0)
 ;;=5^Hx of CHF
 ;;^UTILITY(U,$J,358.3,20510,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,20511,0)
 ;;=V45.81^^131^1289^29
 ;;^UTILITY(U,$J,358.3,20511,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20511,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,20511,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,20511,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,20512,0)
 ;;=V15.84^^131^1289^28
 ;;^UTILITY(U,$J,358.3,20512,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20512,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,20512,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,20512,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,20513,0)
 ;;=V15.85^^131^1289^47
 ;;^UTILITY(U,$J,358.3,20513,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20513,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,20513,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,20513,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,20514,0)
 ;;=V10.72^^131^1289^34
 ;;^UTILITY(U,$J,358.3,20514,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20514,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,20514,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,20514,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,20515,0)
 ;;=V15.3^^131^1289^35
 ;;^UTILITY(U,$J,358.3,20515,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20515,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,20515,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,20515,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,20516,0)
 ;;=V10.61^^131^1289^37
 ;;^UTILITY(U,$J,358.3,20516,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20516,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,20516,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,20516,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,20517,0)
 ;;=V12.03^^131^1289^39
 ;;^UTILITY(U,$J,358.3,20517,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20517,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,20517,1,5,0)
 ;;=5^Hx of Malaria
 ;;^UTILITY(U,$J,358.3,20517,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,20518,0)
 ;;=V10.82^^131^1289^40
 ;;^UTILITY(U,$J,358.3,20518,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20518,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,20518,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,20518,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,20519,0)
 ;;=V10.62^^131^1289^43
 ;;^UTILITY(U,$J,358.3,20519,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20519,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,20519,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,20519,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,20520,0)
 ;;=V10.63^^131^1289^41
 ;;^UTILITY(U,$J,358.3,20520,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20520,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,20520,1,5,0)
 ;;=5^Hx of Monocytic Leukemia
